Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

TRex Bio

Request full access

Treg therapies for autoimmune and inflammatory diseases

South San Francisco, United StatesFounded 2018Biotech & Life Sciences

About TRex Bio

TRexBio develops immunoregulatory medicines intended to restore immune balance in autoimmune and inflammatory diseases by acting on regulatory T cells in affected tissues. Its Deep Biology platform analyses gene expression, pathway activity and cell states in human tissue to identify where Treg function is disrupted and to inform target selection.

The lead wholly owned candidate, TRB-061, is a TNFR2 agonist designed to activate and expand Tregs in inflamed tissue, initially for moderate-to-severe atopic dermatitis. A second candidate, TRB-071, is a CD30 agonist designed to augment tissue Tregs and block inflammatory signalling. The company is based in South San Francisco and was founded in 2018, with scientific origins in tissue Treg biology at UCSF.

Source: Dealroom company data

At a glance

Status
Operational
Employees
61
Open positions
2
Dealroom signal
48.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jan 2026 $50M $420M Polaris Partners · Alexandria Venture Investments · Janus Henderson Investors · Balyasny Asset Management ↗
SERIES BOther financing Nov 2024 $84M $336M Polaris Partners · Johnson & Johnson Innovation · SV Health Investors · Alexandria Venture Investments ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

TRex Bio website traffic

Latest recorded traffic for TRex Bio is 8.9K monthly website visits, up 147.2% over the last three months. TRex Bio's team grew 5.2% over the past year.

Latest monthly visits8.9K 3-month web change+147.2% 1-year team growth+5.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

TRex Bio in the South San Francisco ecosystem

Live from Dealroom

The TRex Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • SV Health Investors
  • Pfizer Ventures
  • Johnson & Johnson Innovation
  • Alexandria Venture Investments
  • Eli Lilly
  • Polaris Partners
  • Laurion Capital Management
  • Delos Capital
  • Agent Capital
  • Avego Bioscience Capital

Series B and later3 investors entered at this stage

Other known investors1 additional known investor

  • University of Oxford
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about TRex Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TRex Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.